



Effect of modulation of serotonergic, cholinergic, and nitroergic pathways on murine fundic size and compliance measured by ultrasonomicrometry

Lin Xue, G. Richard Locke, Michael Camilleri, Jan A. J. Schuurkes, Ann Meulemans, Bernard J. Coulie, Joseph H. Szurszewski and Gianrico Farrugia
AJP - GI 290:74-82, 2006. First published Sep 15, 2005; doi:10.1152/ajpgi.00244.2005

You might find this additional information useful...

This article cites 41 articles, 15 of which you can access free at:

<http://ajpgi.physiology.org/cgi/content/full/290/1/G74#BIBL>

Updated information and services including high-resolution figures, can be found at:

<http://ajpgi.physiology.org/cgi/content/full/290/1/G74>

Additional material and information about *AJP - Gastrointestinal and Liver Physiology* can be found at:

<http://www.the-aps.org/publications/ajpgi>

This information is current as of December 16, 2005 .



Effect of modulation of serotonergic, cholinergic, and nitrergic pathways on murine fundic size and compliance measured by ultrasonomicrometry

Lin Xue,¹ G. Richard Locke,¹ Michael Camilleri,¹ Jan A. J. Schuurkes,² Ann Meulemans,² Bernard J. Coulie,² Joseph H. Szurszewski,¹ and Gianrico Farrugia¹

¹Enteric NeuroScience Program, Mayo Clinic College of Medicine, Rochester, Minnesota; and ²Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium

Submitted 26 May 2005; accepted in final form 7 September 2005

Xue, Lin, G. Richard Locke, Michael Camilleri, Jan A. J. Schuurkes, Ann Meulemans, Bernard J. Coulie, Joseph H. Szurszewski, and Gianrico Farrugia. Effect of modulation of serotonergic, cholinergic, and nitrergic pathways on murine fundic size and compliance measured by ultrasonomicrometry. *Am J Physiol Gastrointest Liver Physiol* 290: G74–G82, 2006. First published September 15, 2005; doi:10.1152/ajpgi.00244.2005.—Reduced fasting or postprandial gastric volumes have been implicated in the pathophysiology of functional dyspepsia. The mechanisms that underlie the control of gastric fundic volume are incompletely understood, partly because of an inability to accurately measure fundic volume in vivo in small animals. Small animals are useful models to evaluate mechanisms, e.g., in knockout animals. The aim of this study was to determine whether an ultrasonometric technique accurately monitors fundic contraction and relaxation in mice in vivo and to determine the effect of modulation of cholinergic, nitrergic, and serotonergic pathways on fundic size and compliance in the intact mouse innervated stomach. Two to four piezoelectric crystals (diameter 1 mm, 24- μ m resolution) were glued to the serosal side of fundus and used to measure distance. Validation studies showed excellent correlation between measured changes and actual changes in distances between crystals and excellent reproducibility. The expected responses to pharmacological modulation with bethanechol and nitroglycerin were demonstrated. Atropine increased the distance between the crystals, suggesting a baseline cholinergic regulation of fundic volume. Bethanechol, *N*^o-nitro-L-arginine, and the 5-HT_{1B/D} agonist sumatriptan decreased the distance between the crystals, suggesting fundic contraction. Atropine, nitroglycerin, and buspirone caused an increase in intercrystal distance consistent with fundic relaxation. Fundic compliance was investigated by changing intragastric pressure via an implanted catheter. Sumatriptan increased compliance, whereas buspirone increased the distance between crystals but did not change compliance. The data suggest that ultrasonomicrometry is a useful tool that can reproducibly and accurately measure changes in fundic size and the response to pharmacological agents.

ultrasound; smooth muscle; gastric fundus; serotonin

THE THREE MAIN MOTOR FUNCTIONS of the human stomach are to accommodate food ingested at mealtimes, triturate food, and mix the content with digestive enzymes and acid. Gastric accommodation includes receptive relaxation and adaptive relaxation. Receptive relaxation allows the stomach to initially accommodate the volume of a meal without a rise in intragastric pressure (IGP) (9, 21), whereas adaptive relaxation is a slower response that may be modulated by the physical and chemical properties

of the meal ingested (13, 25) and the neurohormonal responses to the meal.

Impaired fundic accommodation can occur as a result of vagal injury or a vagotomy and is also present in about a third of patients with functional dyspepsia (3, 34, 36, 37). Fundic accommodation requires an intact extrinsic innervation, predominantly but not exclusively, through vagovagal reflexes and a complex interaction among enteric nerves, gastric mucosa, muscularis propria, smooth muscle cells, and interstitial cells of Cajal (4, 35, 39). In several species, including humans, the neurotransmitters involved include nitric oxide (NO) and serotonin (5-HT) (18, 19, 32, 40). An intact nitrergic pathway is also required for fundic relaxation in the isolated murine fundus (11, 14, 28, 31, 33). However, the mouse fundic data were obtained in muscle strips. The 5-HT receptor agonists buspirone and sumatriptan have been used in clinical studies (7, 16) to treat functional dyspepsia by targeting fundic relaxation. Buspirone is a 5-HT_{1A} agonist and sumatriptan is a 5-HT_{1B/D} agonist, although it is also clear that both act on more than one 5-HT receptor subtype (24). The relative contributions of central and peripheral mechanisms of action of both drugs have not been well defined. Research on the neuronal and nonneuronal pathways that lead to fundic accommodation is hampered by the lack of an accurate, reliable, and reproducible method to study fundic accommodation in small animals in vivo. Ultrasonography, single photon emission computed tomography, and the barostat (13) are used in vivo in larger animals, including humans, but their utility is severely limited in smaller animals such as mice. A recent study (30) developed a miniaturized method to assess gastric tone and compliance using a barostat. The ready availability of knockin and knockout mice makes the mouse model an attractive model to dissect out the pathways that contribute to fundic accommodation. Testing and validation of a method to accurately measure in vivo changes in murine fundic size and determination of the effect of cholinergic, nitrergic, and serotonergic pathways on fundic size in the intact innervated murine stomach are therefore of considerable interest.

In the present study, we utilized an ultrasound technique, known as ultrasonomicrometry, to determine changes in distance between piezoelectric crystals attached to the serosal surface of the murine fundus. The methodology was used to determine the effect of modulation of the major pathways that control fundic size in larger intact animals.

Address for reprint requests and other correspondence: G. Farrugia, Enteric NeuroScience Program, Div. of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905 (e-mail: farrugia.gianrico@mayo.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Ultrasonomicrometry has previously been successfully used to determine changes in volume in the murine heart (22, 23) and the rat gastric body (1, 2). As the piezoelectric crystals are small, several can be placed on the serosa of the murine stomach, allowing the measurement of ultrasound waves as they pass through the thin wall of the murine fundus without needing to traverse the air-filled lumen. This avoids the current major limitation of conventional transabdominal ultrasonography. Our results show that ultrasonomicrometry can be successfully used to measure fundic size *in vivo* and that the measured changes accurately reflect changes in volume. These data suggest that the technique may be of use in small animal *in vivo* research on fundic and gastric volumes.

METHODS

Animals

All experiments were approved by the Mayo Institutional Animal Care and Use Committee. Adult (6–8 wk) male 129 SvEv mice (Taconic; Gemantown, NY; 20–25 g body wt) were used in all experiments. Their diet was changed to Ensure Plus (Abbott Laboratories; Columbus, OH) with free access to water 48 h before each experiment to make sure the stomach was empty of solid food at the time of the experiment. Mice were anesthetized with ketamine (100 mg/kg im) and xylazine (10 mg/kg im). Every 40 min, half of the initial dosage was readministered. Animals were placed on a custom-built heating pad set at 38°C to control body temperature, and an abdominal midline incision was made. A silicon catheter (outer diameter: 0.9 mm, inner diameter: 0.6 mm) was inserted through a small incision (≈ 1 –2 mm) made in the proximal jejunum about 3–5 cm distal to the pylorus, and the residual stomach content was flushed out with saline. After the stomach was emptied, the tip of the catheter was placed in an area between the fundus and corpus. The catheter was ligated in place with a silk suture that also closed the jejunal incision. The other end of the catheter was connected to a saline column. The height of the column was changed by moving the column up or down to adjust the IGP value. Pressure signals were recorded

using a MicroTip pressure catheter transducer (SPR-524 connected to a TCB-600 pressure control unit, Millar Instruments; Houston, TX) and stored digitally on a personal computer.

Ultrasonomicrometry and IGP Measurements

A digital ultrasound-based measurement system (TRX series 8, Sonometrics; London, Ontario, Canada) was used for this study. For each experiment, two to four piezoelectric crystals (external diameter 1 mm) were glued (VetBond, 3M; St. Paul, MN) to the serosal side of fundus at least 3 mm apart (Fig. 1) and, in specific experiments, to the antrum. Measurements were taken every 15 ns. With a sound speed of 1.54 mm/ μ s through tissue, the resolution was 24 μ m. An oscilloscope was used to adjust the sensitivity of the receivers to capture the first received signal. As each piezoelectric crystal acted as both an emitter and receiver, data were collected from each possible permutation (1:2, 1:3, 1:4, 2:3, 2:4, etc.) between the four piezoelectric crystals. Data were recorded on a personal computer in real time using the provided software (Sonoview, Sonometrics). Postacquisition processing used the same software.

IGP was recorded simultaneously with the data from the piezoelectric crystals and displayed concomitantly to determine the temporal relationship between IGP and changes in fundic size as measured by changes in the distance between the crystals. IGP was adjusted by the infusion of saline through the catheter. The pressure transducer was calibrated before each experiment using a water column (Fig. 1).

Experimental Protocols

After stable traces from the piezoelectric crystals were established, drugs were injected via the tail vein or intramuscularly. When more than one drug was used, a minimum of 20 min separated administration of each drug.

For the *ex vivo* experiments, the mouse stomach ($n = 5$) was removed and placed in normal Krebs solution (at 38°C) bubbled with 3% CO₂ and 97% O₂. A pair of crystals was glued to the fundus (4–7 mm apart). The distal esophagus was ligated with a silk suture, and the proximal duodenum was connected to a 1-ml syringe. Boluses of saline (100 μ l) were injected into the stomach in a stepwise fashion.




Fig. 1. Diagram of the ultrasonomicrometry system and the experimental model. Crystals (1.0 mm diameter, resolution: 24 μ m) were glued to the surface of stomach, and distances between the crystals collected, displayed, and analyzed on a Windows-based computer. Before the measurements, a flexible catheter was placed through the jejunum into stomach and placed between the fundus and body to adjust intragastric pressure (IGP) manually. A pressure control unit is also included in the sketch, from which a MicroTip pressure transducer was inserted into the mouse stomach along with the catheter. Pressure signals were also displayed on the computer monitor.

The changes in distance between the crystals was recorded digitally and plotted against the injected volume. In the *in vivo* experiments, the mice ($n = 5$) were anesthetized, the stomach exposed, and the crystals were placed on the fundus *in situ*. A similar protocol to the one described above was then used.

To measure compliance, IGP was adjusted at the beginning of an experiment to 60 mmH₂O (≈ 4.41 mmHg) by infusing prewarmed saline solution into the stomach; 60 mmH₂O was chosen as the initial IGP because, in agreement with the literature (30), at this pressure both contractions and relaxations could be most easily observed. After a 10- to 15-min equilibration period, the IGP was increased in a stepwise fashion by 10 mmH₂O (0.73 mmHg) to a maximum of 100 mmH₂O (Fig. 2). At least 6 min separated each increase in IGP. The 6-min time period was chosen based on preliminary experiments that showed that steady state was reached in this time period. Changes in distances between crystals (dl) and IGP were continuously recorded, and the intercrystal distance (ICD) and the change in IGP (10 mmH₂O) were used to calculate compliance (dl/dp) and plotted (Fig. 2*B,a*).

The gastric fundus is not only compliant but also actively relaxes to accommodate food. Disorders in fundic function may therefore not only include abnormal compliance but also impaired, delayed, or slowed receptive relaxation. To quantify the rate of relaxation, we also measured the rate of the change in distance between the crystals, i.e., the fundic distension rate (FDR), in response to a given initial pressure. The FDR was calculated from the change in length over time (dl/dt). Values of dl/dt were determined by calculating the fit of the slope of the trace (25–75%) in response to any given pressure change (fig. 2*B,b*).

Drugs

Atropine sulphate, bethanechol chloride, and *N*^ω-nitro-L-arginine (L-NNA) were purchased from Sigma (St. Louis, MO). Nitroglycerin was purchased from American Regent Laboratory. Buspirone hydrochloride was purchased from Tocris (Ellisville, MO), and sumatriptan succinate was purchased from GlaxoWellcome (Research Triangle Park, NC).

All drugs were given intravenously via the tail vein except for atropine, which was given intramuscularly. The doses used were

0.2–0.4 mg/kg atropine, 0.15 mg/kg bethanechol, 0.1–0.3 mg/kg sumatriptan, 0.1–0.3 mg/kg buspirone, 0.03 mg/kg nitroglycerin, and 0.5–1.5 mg/kg L-NNA. Doses were selected based on our previous work and on published data (5, 6, 10, 15, 17, 20, 26, 42).

Statistical Analysis

All results are reported as means \pm SE. The number of individual experiments is indicated by the n value. Statistical significance was determined using paired Student's *t*-tests for changes in ICD in response a drug. An unpaired *t*-test was used for the compliance and FDR data. A *P* value of <0.05 was considered significant.

RESULTS

Validation Studies

A series of validation studies was carried out to determine whether the recorded values for the change in distance between the crystals correlated to the actual changes in the distance between the crystals. In the first set of experiments, the upper part of a finger of a rubber glove was cut off and attached to the tip of a 12-ml syringe. Two crystals were glued on the glove tip 10 mm apart using VetBond. The setup was placed under a dissecting microscope equipped with a micrometer. The syringe was used to inject water into the glove tip, and the distance between the two crystals at different injected volumes was directly measured and also measured using the ultrasonomicrometry system ($n = 3$). As can be seen in Fig. 3, there was a 1:1 correlation between the two measurements, suggesting that the ultrasonomicrometry measurements accurately reflected changes in distance between the two crystals.

A second validation study was carried out to determine the correlation between the changes in distance between two crystals placed on the curved surface of the mouse fundus and the volume of the stomach. This set of experiments was carried out both *ex vivo* on the excised stomach and *in vivo* as outlined in METHODS. As can be seen in Fig. 3*B*, increases in gastric volume




Fig. 2. Experimental protocol used to determine compliance in the mouse fundus. After basal IGP was set to 60 mmH₂O, the IGP was increased by 10-mmH₂O increments every 6 min up to 100 mmH₂O. *A*: typical trace and the protocol used. *B,a*: relationship between IGP and intercrystal distance (ICD) for 5 control mice. The slope of the regression line represents the compliance of the fundus. *B,b*: relationship between the fundic distension rate (FDR) and IGP. Numbers in *A* are in mmH₂O.




Fig. 3. In vitro, ex vivo, and in vivo validation of the accuracy of ultrasonomicrometry. **A**: correlation between distance between two crystals attached to a glove tip, measured using a micrometer, to changes in distance measured using the ultrasonomicrometry system ($n = 3$). A 1:1 ratio was obtained, suggesting that ultrasonomicrometry accurately measured distance. **B,a**: correlation between distance between two crystals placed across the dome of the fundus and volume changes in an isolated stomach ($n = 5$). **B,b**: similar experiment but in vivo with the crystals placed on the stomach after laparotomy ($n = 4$). Known volumes of saline were added to the isolated mouse stomach to induce volume changes. There was good correlation between the two measurements in both experiments.

within the physiological range of the murine stomach also resulted in proportional changes in linear distance between two crystals ($n = 5$ for each experiment).

Pharmacological modulation. In a third set of experiments, to determine the biological responsiveness of the technique, bethanechol was used to contract the fundus, and nitroglycerin, a NO donor, was used to relax the fundus (Fig. 4). These experiments were carried out in vivo. Bethanechol (0.15 mg/kg iv) caused a rapid decrease in the distance between the crystals, indicating fundic contraction ($9.7 \pm 2.9\%$, $n = 3$, $P < 0.05$; Fig. 4). Nitroglycerin (0.03 mg/kg iv) caused an increase in the distance between the crystals, indicating relaxation ($4.6 \pm 1.8\%$, $n = 5$, $P < 0.05$; Fig. 4). Atropine (0.2 mg/kg im) also caused an increase in the distance between the crystals ($5.5 \pm 0.9\%$, $n = 8$, $P < 0.05$; Fig. 4), suggesting that there was endogenous cholinergic input to baseline fundic tone.

It is possible that a change in fundic volume may reflect a passive response to a contraction or relaxation in other regions of the stomach. A strong antral contraction may displace enough gastric content proximally to distend the fundus. To investigate this possibility, an additional two crystals were placed on the antral surface. Changes in fundic ICD were not accompanied by inverse changes in the antrum, suggesting that the results represented a direct effect of the drugs on the fundus (data not shown).

Reproducibility. We next determined the reproducibility of our measurements. In this set of experiments, IGP was increased in a stepwise fashion from 60 to 100 mmH₂O as previously described, and distance between the fundic crystals was measured (Fig. 5). The IGP was then returned to baseline, and the experiment was repeated. As can be seen in Fig. 5, there was close to 1:1 correlation both between the rate of change and absolute change in distances between the two sets of data.





Fig. 4. Representative traces of changes in ICD during the administration of bethanechol (**A**), atropine (**B**), and nitroglycerin (**C**). The initial IGP was set to 60 mmH₂O. An upward deflection reflects an increase in ICD (increased fundic size), and a downward deflection reflects a decrease in ICD. Bethanechol decreased the ICD, suggesting that it decreased fundic size, whereas nitroglycerin administration increased the ICD, suggesting that it increased fundic size. Atropine also increased the ICD, suggesting a baseline cholinergic regulation of fundic tone.

Fig. 5. Reproducibility of compliance measurements obtained by stepwise increases in IGP. *A*: changes in ICD induced by stepwise changes in IGP. After 30 min, the protocol was repeated, and the slope of both experiments was plotted (*B*). The slopes were nearly identical, suggesting excellent reproducibility. Numbers are in mmH₂O.



In Vivo Measurement of Changes in Baseline Fundic Volume

As described in METHODS, after the midline incision and placement of the crystals, the anesthetized mice were left to recover for about 30 min when the traces from all the channels reached a stable level. In about half of all animals assessed, regular oscillations in ICD, reflecting a change in fundic size, accompanied by changes in IGP (Fig. 6A), were recorded.

These oscillations initially suggested spontaneous fundic contractions. Changes in ICD were about 25–33% of those recorded from the antrum (data not shown). However, peaks in IGP preceded each increase in the distance between the crystals (Fig. 6B). The peaks in apparent fundic contraction (smallest distance between the crystals) coincided with the lowest IGP recordings, suggesting that the observed “contractions” superimposed on the slower changes in fundic size reflected contractile changes in the distal stomach and not spontaneous fundic contractions.




Fig. 6. Oscillations in fundic ICD associated with changes in IGP. *A*: spontaneous rhythmic changes in ICD associated with changes in IGP. *B*: an expanded trace to highlight the temporal relationship between the apparent fundic contractions and IGP. Peak IGP (dashed line) occurred before peak changes in ICD and was lowest when ICD was lowest, suggesting that the observed rhythmic activity observed in the fundus, superimposed on slower changes, reflected a passive response to contractions in the distal stomach.

In Vivo Measurement of Compliance

Fundic compliance was first determined in controls. Fundic compliance was $9.1 \pm 0.69 \mu\text{m}/\text{mmH}_2\text{O}$ ($n = 26$ preparations). As drugs were administered intravenously in 15–30 μl of saline, we tested the effect of 25 μl NaCl 0.9% (iv) on fundic compliance. No effect was noted (Table 1). We tested the effects of atropine, bethanecol, and L-NNA on fundic compliance to determine the effect of cholinergic and nitregic input on compliance. Atropine (0.4 mg/kg im) immediately increased the size of the fundus but did not alter compliance (Table 1). Bethanecol (0.15 mg/kg iv) and L-NNA (1.5 mg/kg iv) significantly reduced fundic compliance (Table 1).

In Vivo Measurement of FDR

The rate of fundic distension was calculated from the slope of each trace at each IGP. Bethanecol and atropine were used to assess the influence of cholinergic pathways, and L-NNA was used to assess the influence of nitregic pathways on the fundus. The results before and after administration of each drug are summarized in Table 2. As previously shown, atropine immediately increased ICD but did not alter the rate of fundic distension. Bethanecol and L-NNA reduced the rate of fundic distension.

Nitregic Relaxation of the Fundus

To determine the role of the nitregic pathway in fundic relaxation in the intact mouse, we examined the effect of L-NNA on the fundus using somomicrometry in vivo. A decrease in ICD, suggesting contraction of the fundus, was only seen in mice in which there was no initial adjustment of the IGP to 60 mmH₂O (Fig. 7A). In these experiments, no saline

Table 1. Effect of drugs on fundic compliance

	Saline (25 μ l iv)	Sumatriptan (0.1 mg/kg iv)	Buspiron (0.1 mg/kg iv)	Atropine (0.4 mg/kg im)	Bethanechol (0.15 mg/kg iv)	L-NNA (1.5 mg/kg iv)
Control	9.2 \pm 2.6 (3)	7.8 \pm 1.6 (9)	9.9 \pm 2.8 (4)	9.1 \pm 2.5 (4)	8.7 \pm 1.8 (3)	9.3 \pm 1.1 (3)
Experiment	8.9 \pm 1.8 (3)	10.4 \pm 1.8 (9)*	8.4 \pm 8.4 (4)	7.7 \pm 1.4 (4)	3.4 \pm 0.8 (3)*	3.7 \pm 1.3 (3)*

Values are means \pm SE (in μ m/mmH₂O); numbers in parentheses indicate number of animals. L-NNA, *N*^ω-nitro-L-arginine. **P* < 0.05 compared with control.

was infused into the stomach, and IGP was left at baseline. Surprisingly, when the initial IGP was set as 60 mmH₂O, administration of L-NNA (1.5 mg/kg iv) increased ICD, suggesting relaxation of the fundus (2.8 \pm 0.4%, *n* = 3, *P* < 0.05). When distal gastric size was monitored with crystals placed on the antrum, an antral contraction was always seen with L-NNA, and, when IGP was measured, IGP increased on administration of L-NNA (Fig. 7B). It is therefore likely that the paradoxical increase in fundic size on delivery of L-NNA was due to a passive distension induced by movement of fluid from the distal stomach to the proximal stomach and that the direct effect of L-NNA on the fundus was a decrease in fundic size.

As reported above, the ICD in the fundus was initially greater in the presence of L-NNA (1.5 mg/kg iv) but, in contrast to the predrug experiment, did not substantially change as IGP was increased, suggesting a stiffer, nonrelaxing fundus in the presence of L-NNA (Fig. 7C).

Effect of Buspirone and Sumatriptan on Fundic Size and Compliance

Buspirone (0.2 mg/kg iv) increased the distance between crystals (3.5% \pm 0.6%, *n* = 10, *P* < 0.04; Fig. 8), suggesting increased size of the fundus. In contrast, sumatriptan (0.1 mg/kg iv) decreased the distance between crystals (2.6% \pm 0.8% *n* = 10, *P* < 0.05), suggesting a decrease in fundic size (Fig. 8). The discrepancy between our results with sumatriptan and results using the barostat in human and larger animals, which showed fundic relaxation (8, 11), prompted us to further investigate the actions of both drugs on compliance and rate of fundic relaxation. Sumatriptan increased both the compliance (*dI/dp*: 7.8 \pm 1.6 vs 10.4 \pm 1.9 μ m/mmH₂O, *n* = 9, *P* < 0.05; Table 1) and the rate of fundic distension to given pressures

(*dI/dt*; Table 2). The results from a typical experiment are shown in Fig. 9. Although sumatriptan decreased ICD, suggesting it contracted the fundus, both *dI/dp* and *dI/dt* were increased. In contrast, buspirone increased the distance between the crystals, suggesting an increase in fundic size, but did not subsequently change compliance (*dI/dp*: 9.9 \pm 2.8 vs. 8.4 \pm 8.4 μ m/mmH₂O, *n* = 4 *P* > 0.05), nor was there any significant change in the rate of fundic distension to a given pressure (*dI/dp* and *dI/dt*; see Tables 1 and 2 for details).

DISCUSSION

The main aims of the present study were to determine whether ultrasonomicrometry can be used to measure changes in mouse fundic size and to determine the effect of modulation of cholinergic, nitrenergic, and serotonergic pathways on fundic size and compliance in the intact innervated murine stomach. Our results show that ultrasonomicrometry accurately measures changes in fundic size and is able to capture changes in size induced by pharmacological interventions. Our results also show that there is a baseline cholinergic tone in the murine fundus and that nitrenergic and serotonergic pathways affect fundic size and compliance.


Ultrasonomicrometry has advantages compared with current methodologies used to determine changes in fundic size. The technique can be applied to small animals as the spatial resolution is very good and the individual piezoelectric crystals are small. The spatial resolution in ultrasonomicrometry is determined by the speed of the sound energy and the time intervals at which the transit of the signal is measured. The transit speed of sound in most biological material is 1.54 mm/ μ s. The equipment used recorded data every 15 ns, giving a spatial resolution of about 24 μ m. This resolution allows

Table 2. Effects of drugs on fundic distension rate

	IGP, mmH ₂ O			
	10	20	30	40
Sumatriptan treatment				
Control	12.4 \pm 4.9 (9)	11.6 \pm 3.9 (9)	26.8 \pm 8.9 (9)	37.5 \pm 10.5 (9)
Sumatriptan (0.1 mg/kg iv)	7.1 \pm 1.2 (9)	24.6 \pm 5.8 (9)†	49.3 \pm 12.8 (9)*	59.2 \pm 12.9 (9)†
Buspirone treatment				
Control	9.9 \pm 5.9 (4)	15.8 \pm 7.6 (4)	21.3 \pm 9.1 (4)	34.2 \pm 13.7 (4)
Buspirone (0.1 mg/kg iv)	12.6 \pm 8.0 (4)	24.1 \pm 20 (4)	30.8 \pm 21.8 (4)	41.1 \pm 17.3 (4)
Atropine treatment				
Control	5.3 \pm 4.4 (4)	13.0 \pm 11.4 (4)	21.1 \pm 15.7 (4)	29.8 \pm 19.1 (4)
Atropine (0.4 mg/kg im)	4.9 \pm 1.3 (4)	11.5 \pm 0.7 (4)	16.7 \pm 7.7 (4)	30.8 \pm 18.2 (4)
Bethanechol treatment				
Control	8.4 \pm 3.0 (3)	13.2 \pm 2.6 (3)	16.2 \pm 1.0 (3)	16.1 \pm 1.8 (3)
Bethanechol (0.15 mg/kg iv)	-21.6 \pm 17.8 (3)	0.7 \pm 1.5 (3)*	3.0 \pm 0.6 (3)*	7.2 \pm 1.8 (3)†
L-NNA treatment				
Control	15.5 \pm 3.1 (5)	24.5 \pm 3.4 (5)	38.1 \pm 4.8 (5)	43.8 \pm 5.1 (5)
L-NNA (1.5 mg/kg iv)	-2.4 \pm 1.4 (3)*	-1.2 \pm 1.5 (3)*	10.1 \pm 2.3 (3)*	7.4 \pm 3.5 (3)†

Values are means \pm SE (in μ m/min); numbers in parentheses indicate numbers of animals. Intra-gastric pressure (IGP) is the pressure above baseline (60 mmH₂O). **P* < 0.05; †*P* < 0.001.

Fig. 7. Effect of the nitric oxide synthase inhibitor *N*^ω-nitro-L-arginine (L-NNA) on fundic tone and wall compliance. L-NNA (1.0 mg/kg iv) decreased the ICD of crystals placed on the fundus of an empty stomach with no perturbation of the IGP, indicating a contractile effect on the fundus (A). In contrast, when the stomach IGP was set to 60 mmH₂O, L-NNA increased the fundic ICD (B, solid trace). This increase in ICD was preceded by a decrease in the ICD of crystals placed on the antrum (B, gray trace) and by an increase in IGP (B, shaded area). L-NNA also decreased the compliance of the gastric fundus, suggesting a stiffer fundic wall (C).



measurement of small changes in the size of the fundus not usually apparent with other methods. The crystals used in the present study were 1 mm in diameter, allowing several to be placed on the surface of the murine fundus and body of the stomach. Each crystal serves as both a receiver and a transmitter, enabling distances to be calculated from any one crystal to

any other crystal. The crystals measure the sound signal as it passes through the wall of the organ studied, thereby avoiding the problem faced by conventional ultrasonography, which relies on sound energy transmission through the whole organ.




Fig. 8. Representative traces of the effect of the 5-HT_{1A} receptor agonist buspirone (A) and the 5-HT_{1B/D} agonist sumatriptan (B) on the murine fundus. The initial IGP was set to 60 mmH₂O. Buspirone (0.12 mg/kg iv) caused an increase in ICD, suggesting an increase in fundic size, whereas sumatriptan (0.1 mg/kg iv) decreased ICD, suggesting a decrease in fundic size.




Fig. 9. Effect of the 5-HT_{1A} receptor agonist buspirone (A) and the 5-HT_{1B/D} agonist sumatriptan (B) on fundic compliance. Buspirone (A; predrug: solid line; postdrug: gray line, 0.15 mg/kg iv) initially increased the ICD, suggesting that it increased fundic size but did not subsequently alter compliance. Sumatriptan (0.1 mg/kg iv) initially decreased ICD, suggesting that it increased fundic size but, in contrast with buspirone, subsequently increased fundic compliance (B; predrug: solid line; postdrug: gray line). CTRL, control.

Therefore, air within the stomach, particularly the fundus (which often contains air), does not interfere with the ability to record the signal or to determine fundic size. A significant advantage over current methodology is that the technique can be used in small animals with intact extrinsic innervation. This is of particular importance when studying physiological processes, such as fundic accommodation, that require intact vagovagal reflexes (4, 35, 39). These reflexes are lost in muscle strip experiments or in experiments on the isolated stomach.

Fundic compliance (dV/dp) measures the deformability of the fundus by measuring the volume change resulting from a pressure change. Compliance is widely used to evaluate the distensibility of hollow organs such as the gastrointestinal tract, lungs, heart, and bladder. In the present study, in addition to measuring compliance, we also reported on another coefficient, FDR (dV/dt), which was used to provide a measure of the kinetics of distensibility. The value of the FDR is inversely proportionate to the dynamic changes in resistance to distensibility of the fundic wall. This resistance has a passive component from structures that make up the fundic wall and an active component as a result of interactions between enteric nerves, interstitial cells of Cajal, and smooth muscle cells. The FDR coefficient provides information in addition to the fundic compliance coefficient as it is an expression of compliance without requiring a static measure of maximum distension. FDR gives a measure of the rate of distension in response to a given pressure. As is seen in Table 2, FDR varied at different pressure points with a threefold increase in FDR at 40 compared with 10 mmH₂O, likely reflecting active accommodation, thereby reducing resistance to distension.

As we developed the techniques required to measure changes in fundic size, we encountered limitations to the methodology. Our studies were carried out in the acute setting with anesthetized mice. In separate experiments (data not shown), we used mouse antral muscle strips to determine the effect of various anesthetics on contractile activity. We tested all anesthetic drugs currently approved by our institution for use in mice, including diazepam, ketamine, pentobarbital, thiopental, and thiamylal at the recommended doses. All anesthetic drugs tested affected contractile activity, decreasing contractile amplitude. The combination of ketamine and xylazine had the least effect on spontaneous activity and was therefore used in this study.

Another limitation of the ultrasonomicrometry technique is that it does not directly measure IGP. This limitation was highlighted in our experiments with L-NNA as a NO synthase inhibitor. L-NNA would be expected to reduce NO production and therefore cause the fundus to contract. In contrast, an apparent relaxation was seen. Use of an IGP monitoring device and placement of additional crystals on the distal body of the stomach showed that L-NNA caused contraction of the gastric body, resulting in displacement of fluid from the stiffer distal stomach to the more compliant proximal stomach, thereby distending the fundus. These results suggest that it is important to monitor IGP simultaneously when using ultrasonomicrometry in all experiments. Moreover, while the technique has been successfully used to isolate longitudinal and circular muscle contraction or relaxation by placing crystals along the axis of contraction (2), this is harder to accomplish in the fundus. This is due to the spherical nature of the fundus, making the axis of contraction different in different parts of the fundus. We

therefore did not attempt to separate out the contribution of each muscle layer to the changes observed.

The experiments directed toward determining the effect of modulation of cholinergic, nitrergic, and serotonergic pathways on murine fundic size and compliance in the intact innervated stomach revealed different contributions of each pathway to regulation of fundic tone. As previously shown (38), there appears to be a baseline cholinergic input maintaining fundic tone as atropine resulted in an increase in ICD, suggesting relaxation. The data obtained using L-NNA to inhibit NO production while monitoring IGP and antral size are also in agreement with those obtained in other intact animals, including humans (32, 40). Furthermore, L-NNA decreased fundic compliance and markedly altered the rate of fundic relaxation to a given pressure, suggesting that there also was a baseline nitrergic input to fundic smooth muscle and that, in the absence of NO, the fundus is stiffer and nonrelaxing. A serotonergic modulation of fundic tone has been previously reported (27, 29, 41). In contrast to data obtained from humans (8) and dogs (12), sumatriptan did not relax the murine fundus. Instead, a decrease in ICD was seen, suggesting a contraction. Sumatriptan did subsequently increase fundic compliance. These data suggest that there are species differences in the serotonergic modulation of fundic size and, although they are different from human and canine data, are similar to those seen in the cat, where sumatriptan also contracts the cat fundus (J. Tack, personal communication).

In summary, the validation experiments carried out in this study show that ultrasonomicrometry accurately measures distance in the mouse fundus, can be used in the intact animal, has an excellent resolution, and can measure the biological responses to drugs when IGP is also monitored. The data obtained with sumatriptan and buspirone also suggest that ultrasonomicrometry can also be used to explore mechanisms of action of drugs. As highlighted by the results obtained with sumatriptan experiments, important species differences may be present in the response of the fundus to a given drug.

GRANTS

This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants DK-52766 and DK-57061 and by a grant from Johnson & Johnson Pharmaceutical Research and Development.

REFERENCES

1. Adelson DW and Million M. Tracking the moveable feast: sonomicrometry and gastrointestinal motility. *News Physiol Sci* 19: 27–32, 2004.
2. Adelson DW, Million M, Kanamoto K, Palanca T, and Tache Y. Coordinated gastric and sphincter motility evoked by intravenous CCK-8 as monitored by ultrasonomicrometry in rats. *Am J Physiol Gastrointest Liver Physiol* 286: G321–G332, 2004.
3. Azpiroz F and Malagelada JR. Gastric tone measured by an electronic barostat in health and postsurgical gastroparesis. *Gastroenterology* 92: 934–943, 1987.
4. Azpiroz F and Malagelada JR. Vagally mediated gastric relaxation induced by intestinal nutrients in the dog. *Am J Physiol Gastrointest Liver Physiol* 251: G727–G735, 1986.
5. Barocelli E, Ballabeni V, Bertoni S, De Amici M, and Impicciatore M. Evidence for specific analgesic activity of a muscarinic agonist selected among a new series of acetylenic derivatives. *Life Sci* 68: 1775–1785, 2001.
6. Barocelli E, Chiavarini M, Ballabeni V, Barlocco D, Vianello P, Dal Piaz V, and Impicciatore M. Study of the antisecretory and antiulcer mechanisms of a new indenopyridazinone derivative in rats. *Pharmacol Res* 35: 487–492, 1997.



7. **Berstad A.** Today's therapy of functional gastrointestinal disorders—does it help? *Eur J Surg Suppl*: 92–97, 1998.
8. **Boeckxstaens GE, Hirsch DP, Kuiken SD, Heisterkamp SH, and Tytgat GN.** The proximal stomach and postprandial symptoms in functional dyspeptics. *Am J Gastroenterol* 97: 40–48, 2002.
9. **Cannon WB, Lieb CW.** The receptive relaxation of the stomach. *Am J Physiol* 29: 267–273., 1911.
10. **Cao BJ and Rodgers RJ.** Comparative behavioural profiles of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze. *Neuropharmacology* 36: 1089–1097, 1997.
11. **Coulie B, Tack J, Sifrim D, Andrioli A, and Janssens J.** Role of nitric oxide in fasting gastric fundus tone and in 5-HT₁ receptor-mediated relaxation of gastric fundus. *Am J Physiol Gastrointest Liver Physiol* 276: G373–G377, 1999.
12. **De Ponti F, Crema F, Moro E, Nardelli G, Frigo G, and Crema A.** Role of 5-HT_{1B/D} receptors in canine gastric accommodation: effect of sumatriptan and 5-HT_{1B/D} receptor antagonists. *Am J Physiol Gastrointest Liver Physiol* 285: G96–G104, 2003.
13. **De Schepper HU, Cremonini F, Chitkara D, and Camilleri M.** Assessment of gastric accommodation: overview and evaluation of current methods. *Neurogastroenterol Motil* 16: 275–285, 2004.
14. **Desai KM, Sessa WC, and Vane JR.** Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. *Nature* 351: 477–479, 1991.
15. **DiMagno MJ, Hao Y, Tsunoda Y, Williams JA, and Owyang C.** Secretagogue-stimulated pancreatic secretion is differentially regulated by constitutive NOS isoforms in mice. *Am J Physiol Gastrointest Liver Physiol* 286: G428–G436, 2004.
16. **Friedman G.** Treatment of the irritable bowel syndrome. *Gastroenterol Clin North Am* 20: 325–333, 1991.
17. **Furfine ES, Harmon MF, Paith JE, and Garvey EP.** Selective inhibition of constitutive nitric oxide synthase by L-N^G-nitroarginine. *Biochemistry* 32: 8512–8517, 1993.
18. **Furness JB and Costa M.** Neurons with 5-hydroxytryptamine-like immunoreactivity in the enteric nervous system: their projections in the guinea-pig small intestine. *Neuroscience* 7: 341–349, 1982.
19. **Gershon MD.** The enteric nervous system: a second brain. *Hosp Pract (Off Ed)* 34: 31–32, 35–38, and 41–32 passim, 1999.
20. **Ghelardini C, Galeotti N, Grazioli I, and Uslenghi C.** Indomethacin, alone and combined with prochlorperazine and caffeine, but not sumatriptan, abolishes peripheral and central sensitization in in vivo models of migraine. *J Pain* 5: 413–419, 2004.
21. **Grey E.** Observations on the postural activity of the stomach. *Am J Physiol* 45: 272–285, 1918.
22. **Guth BD, Schulz R, and Heusch G.** Time course and mechanisms of contractile dysfunction during acute myocardial ischemia. *Circulation* 87: IV35–IV42, 1993.
23. **Hoit BD.** New approaches to phenotypic analysis in adult mice. *J Mol Cell Cardiol* 33: 27–35, 2001.
24. **Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharene EJ, Saxena PR, and Humphrey PP.** International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). *Pharmacol Rev* 46: 157–203, 1994.
25. **Jahnberg T, Abrahamsson H, Jansson G, and Martinson J.** Gastric relaxatory response to feeding before and after vagotomy. *Scand J Gastroenterol* 12: 225–228, 1977.
26. **Kawabata A, Nishikawa H, Kuroda R, Kawai K, and Hollenberg MD.** Proteinase-activated receptor-2 (PAR-2): regulation of salivary and pancreatic exocrine secretion in vivo in rats and mice. *Br J Pharmacol* 129: 1808–1814, 2000.
27. **Kojima S, Ishizaki R, and Shimo Y.** Investigation into the 5-hydroxytryptamine-induced relaxation of the circular smooth muscle of guinea-pig stomach fundus. *Eur J Pharmacol* 224: 45–49, 1992.
28. **Mashimo H, He XD, Huang PL, Fishman MC, and Goyal RK.** Neuronal constitutive nitric oxide synthase is involved in murine enteric inhibitory neurotransmission. *J Clin Invest* 98: 8–13, 1996.
29. **Moen H, Ertresvaag K, and Gerner T.** Motor responses to serotonin in isolated guinea pig fundus and antrum. *Scand J Gastroenterol* 18: 145–149, 1983.
30. **Monroe MJ, Hornby PJ, and Partosoedarso ER.** Central vagal stimulation evokes gastric volume changes in mice: a novel technique using a miniaturized barostat. *Neurogastroenterol Motil* 16: 5–11, 2004.
31. **Selemidis S and Cocks TM.** Nitergic relaxation of the mouse gastric fundus is mediated by cyclic GMP-dependent and ryanodine-sensitive mechanisms. *Br J Pharmacol* 129: 1315–1322, 2000.
32. **Stark ME and Szurszewski JH.** Role of nitric oxide in gastrointestinal and hepatic function and disease. *Gastroenterology* 103: 1928–1949, 1992.
33. **Tack J, Demedts I, Meulemans A, Schuurkes J, and Janssens J.** Role of nitric oxide in the gastric accommodation reflex and in meal induced satiety in humans. *Gut* 51: 219–224, 2002.
34. **Tack J, Piessevaux H, Coulie B, Caenepeel P, and Janssens J.** Role of impaired gastric accommodation to a meal in functional dyspepsia. *Gastroenterology* 115: 1346–1352, 1998.
35. **Takahashi T and Owyang C.** Characterization of vagal pathways mediating gastric accommodation reflex in rats. *J Physiol* 504: 479–488, 1997.
36. **Thumshirn M, Camilleri M, Hanson RB, Williams DE, Schei AJ, and Kammer PP.** Gastric mechanosensory and lower esophageal sphincter function in rumination syndrome. *Am J Physiol Gastrointest Liver Physiol* 275: G314–G321, 1998.
37. **Vu MK, Straathof JW, Schaar PJ, Arndt JW, Ringers J, Lamers CB, and Masclee AA.** Motor and sensory function of the proximal stomach in reflux disease and after laparoscopic Nissen fundoplication. *Am J Gastroenterol* 94: 1481–1489, 1999.
38. **Ward SM, Beckett EA, Wang X, Baker F, Khoyi M, and Sanders KM.** Interstitial cells of Cajal mediate cholinergic neurotransmission from enteric motor neurons. *J Neurosci* 20: 1393–1403, 2000.
39. **Wilbur BG and Kelly KA.** Effect of proximal gastric, complete gastric, and truncal vagotomy on canine gastric electric activity, motility, and emptying. *Ann Surg* 178: 295–303, 1973.
40. **Xue L, Farrugia G, Miller SM, Ferris CD, Snyder SH, and Szurszewski JH.** Carbon monoxide and nitric oxide as coneurotransmitters in the enteric nervous system: evidence from genomic deletion of biosynthetic enzymes. *Proc Natl Acad Sci USA* 97: 1851–1855, 2000.
41. **Xue L, Locke GR, Schuurkes JAJ, Meuleman A, Coulie BJ, Szurszewski JH, and Farrugia G.** Serotonergic modulation of murine fundic tone (Abstract). *Gastroenterology* 124: A580, 2003.
42. **Yuan R, Sumi M, and Benet LZ.** Investigation of aortic CYP3A bioactivation of nitroglycerin in vivo. *J Pharmacol Exp Ther* 281: 1499–1505, 1997.

Downloaded from ajpgi.physiology.org on December 16, 2005